Short Interest in Genmab A/S (NASDAQ:GMAB) Expands By 10.2%

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,050,000 shares, an increase of 10.2% from the February 29th total of 1,860,000 shares. Based on an average trading volume of 623,600 shares, the days-to-cover ratio is presently 3.3 days. Currently, 0.3% of the shares of the company are short sold.

Genmab A/S Stock Performance

GMAB traded down $0.31 on Tuesday, hitting $29.96. 281,668 shares of the company were exchanged, compared to its average volume of 632,139. The business's fifty day moving average is $28.96 and its 200 day moving average is $30.89. The firm has a market capitalization of $19.80 billion, a P/E ratio of 30.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.98. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.34 by $0.02. The business had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. Analysts forecast that Genmab A/S will post 1.09 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Large investors have recently modified their holdings of the business. Keybank National Association OH acquired a new stake in shares of Genmab A/S in the third quarter valued at approximately $1,154,000. Knights of Columbus Asset Advisors LLC grew its position in shares of Genmab A/S by 16.8% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company's stock valued at $201,000 after purchasing an additional 822 shares during the last quarter. Northern Trust Corp grew its position in shares of Genmab A/S by 83.3% in the third quarter. Northern Trust Corp now owns 559,044 shares of the company's stock valued at $19,717,000 after purchasing an additional 254,042 shares during the last quarter. HBK Sorce Advisory LLC lifted its stake in shares of Genmab A/S by 4.8% during the third quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company's stock valued at $322,000 after buying an additional 419 shares during the period. Finally, Schechter Investment Advisors LLC lifted its stake in shares of Genmab A/S by 89.3% during the third quarter. Schechter Investment Advisors LLC now owns 13,707 shares of the company's stock valued at $483,000 after buying an additional 6,466 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GMAB. UBS Group upgraded shares of Genmab A/S from a "neutral" rating to a "buy" rating in a research note on Wednesday, December 6th. BMO Capital Markets upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Truist Financial reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, March 27th. Finally, Citigroup lowered shares of Genmab A/S from a "neutral" rating to a "sell" rating in a research report on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.